An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 08 Sep 2017
At a glance
- Drugs Elamipretide (Primary)
- Indications Dry age-related macular degeneration
- Focus Adverse reactions
- Acronyms ReCLAIM
- Sponsors Stealth BioTherapeutics
- 05 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 07 Mar 2017 Planned End Date changed from 1 Jun 2017 to 1 Mar 2018.
- 07 Mar 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Mar 2018.